Safety Syringes and AstraZeneca launch injectable form of Exanta in Europe

Published: 25-Jun-2004

California-based Safety Syringes and AstraZeneca have launched in Germany oral and injectable Exanta in its first indication prevention of venous thromboembolic events (VTE) in elective hip or knee replacement surgery (orthopaedic surgery).


California-based Safety Syringes and AstraZeneca have launched in Germany oral and injectable Exanta in its first indication prevention of venous thromboembolic events (VTE) in elective hip or knee replacement surgery (orthopaedic surgery).

The European treatment regimen for Exanta involves an early postoperative start of treatment, with initial injectable dosing administered 4-8 hours after the completion of surgery, followed by oral Exanta 24mg twice daily for up to 11 days.

For the injectable form of Exanta (melagatran) AstraZeneca is using the UltraSafe Passive delivery system to enhance protection of health care personnel against blood transmitted diseases. 'Exanta is a new anticoagulant and the first oral treatment in a new class of direct thrombin inhibitors (DTIs),' commented Thomas Rask, global brand manager. 'We found the UltraSafe Passive delivery system to be clearly preferred to standard prefilled syringes because of its safety profile in protecting from needle injuries.'

Designed to enhance user compliance and protection, the UltraSafe Passive delivery system is intended for unit dose, prefilled glass syringe presentations. The easy-to-use, intuitive and innovative system is said to provide an optimal drug delivery system with the preferred passive activation method. The patented UltraSafe delivery system has been marketed since 1999.

  

You may also like